TempraMed Technologies Ltd. News Releases

TempraMed Signs Letter of Intent with CPO Greece for Exclusive Distribution of VIVI Products in Greece

Tue, 01 Sep 2026 06:45:00 -0400

Distribution framework pairs TempraMed's injectable medication-protection products with one of the largest, most established Greek pharmacy and healthcare distributors Highlights:LOI with CPO Greece includes exclusive distribution of VIVI Cap™ and VIVI Epi™ throughout Greece, subject to a definitive agreement.Proposed exclusivity is conditional on minimum annual purchase obligations, with combined purchases required to increase by at least 20% year over year to maintain exclusivity.Transfer...

TempraMed Signs Definitive Five-Year Saudi Arabia Distribution Agreement for Private-Label VIVI Cap

Tue, 25 Aug 2026 07:00:00 -0400

Agreement targets commercialization through the physical retail network of Nahdi Medical Company, Saudi Arabia's largest pharmacy chain. HighlightsFive-year definitive agreement with approximately US$3.8 million in potential minimum purchase commitments, beginning with a firm 10,000-unit initial purchase order.Agreement covers a private-label version of VIVI Cap™ intended for retail commercialization through the physical pharmacy network of Nahdi Medical Company, Saudi Arabia's largest pharmacy...

TempraMed Announces Extension of Maccabi Healthcare Services Agreement

Thu, 20 Aug 2026 07:00:00 -0400

Maccabi exercises option to extend agreement for an additional year, reinforcing continued adoption of TempraMed's medication protection technology Toronto, Ontario--(Newsfile Corp. - August 20, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9DY) ("TempraMed" or the "Company"), a medical technology innovator focused on temperature-sensitive medication protection, is pleased to announce that Maccabi Healthcare Services ("Maccabi"), Israel's second-largest health maintenance...

TempraMed Executes Definitive Exclusive Distribution Agreement with TEM in Panama, Advancing Commercial Expansion Across Clinics and Pharmacies

Tue, 18 Aug 2026 07:00:00 -0400

Agreement transitions previously announced LOI into a definitive commercial relationship First bulk commercial order fulfilled for distribution into clinics and pharmacies TempraMed expands access to its temperature-protection solutions through healthcare channels in PanamaToronto, Ontario--(Newsfile Corp. - August 18, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive...

TempraMed Announces Strategic Partnership with Stealth Health, a Leading Telemedicine Platform for Longevity and Wellness

Tue, 04 Aug 2026 07:00:00 -0400

Integrates VIVI product portfolio into Stealth Health's rapidly expanding direct-to-patient telemedicine platform and enterprise white-label network, providing a solution to keep important medications safe Vancouver, British Columbia--(Newsfile Corp. - August 4, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce a strategic...

TempraMed Uplists to OTCQB Venture Market and Achieves DTC Eligibility, Expanding Access to U.S. Investors

Thu, 30 Jul 2026 07:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - July 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9DY) ("TempraMed" or the "Company") is pleased to announce that its common shares have been approved to commence trading on the OTCQB Venture Market, operated by OTC Markets Group Inc. The Company's shares are also now DTC eligible, significantly enhancing the accessibility and efficiency of trading for U.S. investors.TempraMed common shares trade on the OTCQB under the symbol TMPTF...

TempraMed Expands Institutional Healthcare Network with Meuhedet Health Services, a Leading HMO in Israel, Covering over 1 Million Lives

Thu, 09 Jul 2026 07:00:00 -0400

Acceptance of TempraMed's products by Meuhedet Health Services strengthens TempraMed's B2B institutional commercialization strategy as the Company advances reimbursement initiatives and expands relationships with leading healthcare organizations globally HighlightsMeuhedet Health Services, Israel's third-largest Health Maintenance Organization (HMO), serving more than one million insured members, has accepted TempraMed's flagship VIVI Cap™ and VIVI Epi™ products. TempraMed products are now...

TempraMed Signs LOI for Exclusive Distribution in Kuwait, Expanding Presence in High-Growth Gulf Region Healthcare Market

Mon, 06 Jul 2026 07:00:00 -0400

HighlightsTempraMed signs non-binding LOI for exclusive distribution in Kuwait with Elegir TradingKuwait represents a high-value market with significant demand for insulin, GLP-1 therapies, biologics, and other temperature-sensitive medicationsLOI includes minimum annual purchase commitments in Year 1Expands TempraMed's footprint across the Middle East and supports broader regional commercialization strategyPotential future expansion includes VIVI Med™, VIVI Epi™, and VIVI Cap Smart™...

TempraMed Expands Strategic Partnership with McKesson Medical-Surgical to Accelerate North American Growth and Launch Full Portfolio Across B2B Channels

Tue, 30 Jun 2026 03:05:00 -0400

Integration into McKesson's Medical-Surgical Solutions marketplace serving a nationwide customer base Toronto, Ontario--(Newsfile Corp. - June 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a leader in temperature-controlled medication solutions, is pleased to announce the expansion of its relationship with McKesson Medical-Surgical ("MMS"). The agreement, dated June 23, 2026, broadens the scope of collaboration to include full portfolio...

TempraMed Signs Non-Binding LOI with National Distributor in Saudi Arabia

Fri, 26 Jun 2026 16:10:00 -0400

Strategic Saudi partnership with Rawafed Health International Company targets one of the region's largest diabetes and injectable-therapy markets, supported by leading healthcare infrastructure, pharmacy access in the region Toronto, Ontario--(Newsfile Corp. - June 26, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that it...